Company profile: Anthos Therapeutics
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies for cardiovascular and metabolic diseases, including Abelacimab, an investigational monoclonal antibody that inhibits Factor XI and XIa to provide anticoagulation with reduced bleeding risk for the prevention and treatment of arterial and venous thromboembolic events.
Products and services
- CVM Therapy Development: Develops CVM disease therapies guided by a world-class executive team with extensive development expertise, biopharmaceutical-grade, targeting treatment modalities for cardiovascular and metabolic disorders
- CVM Therapy Commercialization: Commercializes CVM disease therapies leveraging extensive commercialization experience, biopharmaceutical-grade, advancing therapies to market for cardiovascular and metabolic disease treatments
- Abelacimab: Investigational monoclonal antibody that inhibits Factor XI and XIa, engineered to deliver anticoagulation with reduced bleeding risk for prevention and treatment of arterial and venous thromboembolic events
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Anthos Therapeutics
Shape Memory Medical
HQ: United States
Website
- Description: Provider of shape memory polymer–based medical devices for embolization, including IMPEDE Embolization Plug for space filling and occlusion, IMPEDE-FX Embolization Plug for optimized stasis and stable clot formation, IMPEDE-FX RapidFill to quickly occlude large vessels or spaces, and TrelliX Embolic Coil for neurovascular and peripheral use; plus the AAA-SHAPE clinical trial evaluating IMPEDE-FX devices for AAA sac filling outside of an EVAR stent graft.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Shape Memory Medical company profile →
Vascular Dynamics
HQ: United States
Website
- Description: Provider of the MobiusHD endovascular implant and catheter-based EVBA procedure to modulate the baroreflex via carotid sinus placement, aiming to correct inflexible arterial motion to treat hypertension and restore autonomic balance in heart failure patients; also conducts clinical research evaluating the safety and effectiveness of MobiusHD.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vascular Dynamics company profile →
Impella
HQ: Germany
Website
- Description: Provider of minimally invasive cardiovascular support systems for numerous indications in cardiology and coronary surgery. Based in Aachen, Germany, the company develops, manufactures and markets its technology, which is protected by more than 30 European and international patents.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Impella company profile →
Bardy Diagnostics
HQ: United States
Website
- Description: Provider of cardiac monitoring and arrhythmia detection solutions, including the CAM Patch, a lightweight, extended-wear cardiac patch that optimizes P-wave capture for up to 14 days of continuous ECG monitoring; the BDxCONNECT Portal for secure ECG data upload, analysis, and full report delivery; and the CAM Report offering clear, full-disclosure ECG interpretations typically within 48 hours. CAM can be worn during exercise or while showering.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bardy Diagnostics company profile →
Hemosphere
HQ: United States
Website
- Description: Provider of proprietary graft-based vascular access solutions for dialysis, marketing the HeRO (Hemodialysis Reliable Outflow) Graft, a fully subcutaneous arteriovenous access solution for end-stage renal disease hemodialysis patients with limited access options and central venous obstruction, designed to maintain long-term access without venous anastomosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hemosphere company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Anthos Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Anthos Therapeutics
2.2 - Growth funds investing in similar companies to Anthos Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Anthos Therapeutics
4.2 - Public trading comparable groups for Anthos Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →